BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yeo TP. Demographics, epidemiology, and inheritance of pancreatic ductal adenocarcinoma. Semin Oncol. 2015;42:8-18. [PMID: 25726048 DOI: 10.1053/j.seminoncol.2014.12.002] [Cited by in Crossref: 80] [Cited by in F6Publishing: 80] [Article Influence: 10.0] [Reference Citation Analysis]
Number Citing Articles
1 Sánchez Morales GE, Moguel Valladares RA, Flores Maza J, Gutiérrez UC, Sánchez-García Ramos E, Domínguez Rosado I, Chan Núñez LC. Pancreatic ductal adenocarcinoma: Eleven years of experience at a tertiary care hospital center. Rev Gastroenterol Mex (Engl Ed) 2021;86:118-24. [PMID: 32616358 DOI: 10.1016/j.rgmx.2020.04.004] [Reference Citation Analysis]
2 Huang Y, Zhu N, Zheng X, Liu Y, Lu H, Yin X, Hao H, Tan Y, Wang D, Hu H, Liang Y, Li X, Hu Z, Yin Y. Intratumor Microbiome Analysis Identifies Positive Association Between Megasphaera and Survival of Chinese Patients With Pancreatic Ductal Adenocarcinomas. Front Immunol 2022;13:785422. [DOI: 10.3389/fimmu.2022.785422] [Reference Citation Analysis]
3 Wang XY, Chen HT, Na R, Jiang DK, Lin XL, Yang F, Jin C, Fu DL, Xu JF. Single-nucleotide polymorphisms based genetic risk score in the prediction of pancreatic cancer risk. World J Gastroenterol 2020; 26(22): 3076-3086 [PMID: 32587449 DOI: 10.3748/wjg.v26.i22.3076] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Scharwächter C, Haage P. State of the Art Diagnosis of Pancreatic Ductal Adenocarcinoma. Curr Radiol Rep 2017;5. [DOI: 10.1007/s40134-017-0233-9] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
5 Are C, Chowdhury S, Ahmad H, Ravipati A, Song T, Shrikandhe S, Smith L. Predictive global trends in the incidence and mortality of pancreatic cancer based on geographic location, socio-economic status, and demographic shift. J Surg Oncol 2016;114:736-42. [PMID: 27511902 DOI: 10.1002/jso.24410] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 6.0] [Reference Citation Analysis]
6 Permuth JB, Choi JW, Chen DT, Jiang K, DeNicola G, Li JN, Coppola D, Centeno BA, Magliocco A, Balagurunathan Y, Merchant N, Trevino JG, Jeong D. A pilot study of radiologic measures of abdominal adiposity: weighty contributors to early pancreatic carcinogenesis worth evaluating? Cancer Biol Med 2017;14:66-73. [PMID: 28443205 DOI: 10.20892/j.issn.2095-3941.2017.0006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
7 Zhao Z, Liu W. Pancreatic Cancer: A Review of Risk Factors, Diagnosis, and Treatment. Technol Cancer Res Treat 2020;19:1533033820962117. [PMID: 33357065 DOI: 10.1177/1533033820962117] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Dugnani E, Pasquale V, Marra P, Liberati D, Canu T, Perani L, De Sanctis F, Ugel S, Invernizzi F, Citro A, Venturini M, Doglioni C, Esposito A, Piemonti L. Four-class tumor staging for early diagnosis and monitoring of murine pancreatic cancer using magnetic resonance and ultrasound. Carcinogenesis 2018;39:1197-206. [DOI: 10.1093/carcin/bgy094] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
9 Rozich NS, Jones CE, Morris KT. Malnutrition, frailty, and sarcopenia in pancreatic cancer patients: assessments and interventions for the pancreatic surgeon. Ann Pancreat Cancer 2019;2:3. [PMID: 33554109 DOI: 10.21037/apc.2019.02.01] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
10 Lewis CS, Voelkel-Johnson C, Smith CD. Suppression of c-Myc and RRM2 expression in pancreatic cancer cells by the sphingosine kinase-2 inhibitor ABC294640. Oncotarget 2016;7:60181-92. [PMID: 27517489 DOI: 10.18632/oncotarget.11112] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 5.8] [Reference Citation Analysis]
11 Martinez-Useros J, Li W, Cabeza-Morales M, Garcia-Foncillas J. Oxidative Stress: A New Target for Pancreatic Cancer Prognosis and Treatment. J Clin Med 2017;6:E29. [PMID: 28282928 DOI: 10.3390/jcm6030029] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 7.6] [Reference Citation Analysis]
12 Sperlongano P, Esposito E, Esposito A, Clarizia G, Moccia G, Malinconico FA, Foroni F, Manfredi C, Sperlongano S, Gubitosi A. Laparoscopic pancreatectomy: Did the indications change? A review from literature. Int J Surg 2015;21 Suppl 1:S22-5. [PMID: 26123387 DOI: 10.1016/j.ijsu.2015.04.094] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
13 Fiorino S, Bacchi-reggiani ML, Birtolo C, Acquaviva G, Visani M, Fornelli A, Masetti M, Tura A, Sbrignadello S, Grizzi F, Patrinicola F, Zanello M, Mastrangelo L, Lombardi R, Benini C, Di Tommaso L, Bondi A, Monetti F, Siopis E, Orlandi PE, Imbriani M, Fabbri C, Giovanelli S, Domanico A, Accogli E, Di Saverio S, Grifoni D, Cennamo V, Leandri P, Jovine E, de Biase D. Matricellular proteins and survival in patients with pancreatic cancer: A systematic review. Pancreatology 2018;18:122-32. [DOI: 10.1016/j.pan.2017.11.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
14 Haage P, Schwartz CA, Scharwächter C. [Ductal adenocarcinoma and unusual differential diagnosis]. Radiologe 2016;56:325-37. [PMID: 27000276 DOI: 10.1007/s00117-016-0090-1] [Reference Citation Analysis]
15 Nai Y, Pan C, Hu X, Ma Y. LncRNA LUCAT1 contributes to cell proliferation and migration in human pancreatic ductal adenocarcinoma via sponging miR-539. Cancer Med 2020;9:757-67. [PMID: 31789465 DOI: 10.1002/cam4.2724] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
16 Subramani R, Gonzalez E, Nandy SB, Arumugam A, Camacho F, Medel J, Alabi D, Lakshmanaswamy R. Gedunin inhibits pancreatic cancer by altering sonic hedgehog signaling pathway. Oncotarget. 2017;8:10891-10904. [PMID: 26988754 DOI: 10.18632/oncotarget.8055] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 6.2] [Reference Citation Analysis]
17 Birmann BM, Barnard ME, Bertrand KA, Bao Y, Crous-Bou M, Wolpin BM, De Vivo I, Tworoger SS. Nurses' Health Study Contributions on the Epidemiology of Less Common Cancers: Endometrial, Ovarian, Pancreatic, and Hematologic. Am J Public Health 2016;106:1608-15. [PMID: 27459458 DOI: 10.2105/AJPH.2016.303337] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
18 Eissa MAL, Lerner L, Abdelfatah E, Shankar N, Canner JK, Hasan NM, Yaghoobi V, Huang B, Kerner Z, Takaesu F, Wolfgang C, Kwak R, Ruiz M, Tam M, Pisanic TR 2nd, Iacobuzio-Donahue CA, Hruban RH, He J, Wang TH, Wood LD, Sharma A, Ahuja N. Promoter methylation of ADAMTS1 and BNC1 as potential biomarkers for early detection of pancreatic cancer in blood. Clin Epigenetics. 2019;11:59. [PMID: 30953539 DOI: 10.1186/s13148-019-0650-0] [Cited by in Crossref: 38] [Cited by in F6Publishing: 42] [Article Influence: 12.7] [Reference Citation Analysis]
19 Antonios A, Gharios J, Tohme C. Resectable pancreatic adenocarcinomas: will neoadjuvant FOLFIRINOX replace upfront surgery in the standard of care? Future Oncology 2017;13:951-3. [DOI: 10.2217/fon-2017-0050] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
20 Herreros-Villanueva M, Bujanda L. Glypican-1 in exosomes as biomarker for early detection of pancreatic cancer. Ann Transl Med 2016;4:64. [PMID: 27004211 DOI: 10.3978/j.issn.2305-5839.2015.10.39] [Cited by in F6Publishing: 34] [Reference Citation Analysis]
21 Mittal K, Ogden A, Reid MD, Rida PC, Varambally S, Aneja R. Amplified centrosomes may underlie aggressive disease course in pancreatic ductal adenocarcinoma. Cell Cycle 2015;14:2798-809. [PMID: 26151406 DOI: 10.1080/15384101.2015.1068478] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
22 Magouliotis DE, Tasiopoulou VS, Svokos AA, Svokos KA. Aquaporins in health and disease. Adv Clin Chem 2020;98:149-71. [PMID: 32564785 DOI: 10.1016/bs.acc.2020.02.005] [Reference Citation Analysis]
23 Wiest NE, Moktan VP, Oman SP, Chirilă RM. Screening for pancreatic cancer: a review for general clinicians. Rom J Intern Med 2020;58:119-28. [PMID: 32364522 DOI: 10.2478/rjim-2020-0009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Winter K, Talar-Wojnarowska R, Dąbrowski A, Degowska M, Durlik M, Gąsiorowska A, Głuszek S, Jurkowska G, Kaczka A, Lampe P, Marek T, Nasierowska-Guttmejer A, Nowakowska-Duława E, Rydzewska G, Strzelczyk J, Śledziński Z, Małecka-Panas E. Diagnostic and therapeutic recommendations in pancreatic ductal adenocarcinoma. Recommendations of the Working Group of the Polish Pancreatic Club. Prz Gastroenterol 2019;14:1-18. [PMID: 30944673 DOI: 10.5114/pg.2019.83422] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
25 Banerjee J, Papu John AM, Al-Wadei MH, Schuller HM. Prevention of pancreatic cancer in a hamster model by cAMP decrease. Oncotarget 2016;7:44430-41. [PMID: 27281617 DOI: 10.18632/oncotarget.9790] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
26 Fiorino S, Visani M, Masetti M, Acquaviva G, Tallini G, De Leo A, Fornelli A, Ragazzi M, Vasuri F, Grifoni D, Argento CM, Maloberti T, Ravaioli M, Fabbri C, Jovine E, Pession A, de Biase D. Periostin, tenascin, osteopontin isoforms in long- and non-long survival patients with pancreatic cancer: a pilot study. Mol Biol Rep 2020;47:8235-41. [PMID: 32886326 DOI: 10.1007/s11033-020-05763-2] [Reference Citation Analysis]
27 Passeri MJ, Baker EH, Siddiqui IA, Templin MA, Martinie JB, Vrochides D, Iannitti DA. Total compared with partial pancreatectomy for pancreatic adenocarcinoma: assessment of resection margin, readmission rate, and survival from the U.S. National Cancer Database. Curr Oncol 2019;26:e346-56. [PMID: 31285679 DOI: 10.3747/co.26.4066] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
28 Fergadi MP, Magouliotis DE, Rountas C, Vlychou M, Athanasiou T, Symeonidis D, Pappa PA, Zacharoulis D. A meta-analysis evaluating the role of high-intensity focused ultrasound (HIFU) as a fourth treatment modality for patients with locally advanced pancreatic cancer. Abdom Radiol (NY) 2021. [PMID: 34718835 DOI: 10.1007/s00261-021-03334-y] [Reference Citation Analysis]
29 Hamada T, Yuan C, Yurgelun MB, Perez K, Khalaf N, Morales-Oyarvide V, Babic A, Nowak JA, Rubinson DA, Giannakis M, Ng K, Kraft P, Stampfer MJ, Giovannucci EL, Fuchs CS, Ogino S, Wolpin BM. Family history of cancer, Ashkenazi Jewish ancestry, and pancreatic cancer risk. Br J Cancer 2019;120:848-54. [PMID: 30867564 DOI: 10.1038/s41416-019-0426-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
30 Fonseca de Jesus VH, Guedes Camandaroba MP, Spina Donadio MD, Cabral A, Pimentel Muniz T, de Moura Leite L, Ferreira Sant'Ana L, Luiz da Costa W Jr, Curado MP, Coimbra FJF. Clinico-pathological features and survival of patients with malignant exocrine pancreatic neoplasms: The AC Camargo Cancer Center experience. J Surg Oncol 2019;119:71-8. [PMID: 30481379 DOI: 10.1002/jso.25312] [Reference Citation Analysis]
31 Midha S, Chawla S, Garg PK. Modifiable and non-modifiable risk factors for pancreatic cancer: A review. Cancer Lett. 2016;381:269-277. [PMID: 27461582 DOI: 10.1016/j.canlet.2016.07.022] [Cited by in Crossref: 72] [Cited by in F6Publishing: 75] [Article Influence: 12.0] [Reference Citation Analysis]
32 Castel-kremer E, De Talhouet S, Charlois A, Graillot E, Chopin-laly X, Adham M, Comte B, Lombard-bohas C, Walter T, Boschetti G. An onco-geriatric approach to select older patients for optimal treatments of pancreatic adenocarcinoma. Journal of Geriatric Oncology 2018;9:373-81. [DOI: 10.1016/j.jgo.2018.03.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
33 Yu Z, Zhao S, Wang L, Wang J, Zhou J. miRNA-339-5p Plays an Important Role in Invasion and Migration of Pancreatic Cancer Cells. Med Sci Monit 2019;25:7509-17. [PMID: 31588120 DOI: 10.12659/MSM.917038] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
34 Ducreux M, Cuhna AS, Caramella C, Hollebecque A, Burtin P, Goéré D, Seufferlein T, Haustermans K, Van Laethem J, Conroy T, Arnold D. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 2015;26:v56-68. [DOI: 10.1093/annonc/mdv295] [Cited by in Crossref: 525] [Cited by in F6Publishing: 477] [Article Influence: 75.0] [Reference Citation Analysis]
35 Garcia-Carbonero N, Li W, Cabeza-Morales M, Martinez-Useros J, Garcia-Foncillas J. New Hope for Pancreatic Ductal Adenocarcinoma Treatment Targeting Endoplasmic Reticulum Stress Response: A Systematic Review. Int J Mol Sci 2018;19:E2468. [PMID: 30134550 DOI: 10.3390/ijms19092468] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
36 Yeo TP, Lavu H, Nevler A, Brumbaugh J, Vicchairelli D, Winter JM, Brody JR, Yeo CJ. Precious Data: Interim Report from the Jefferson Pancreas Tumor Registry. J Pancreat Cancer 2018;4:17-24. [PMID: 30631853 DOI: 10.1089/pancan.2018.0004] [Reference Citation Analysis]
37 Qian CJ, Chen YY, Zhang X, Liu FQ, Yue TT, Ye B, Yao J. Notch4 inhibition reduces migration and invasion and enhances sensitivity to docetaxel by inhibiting Akt/fascin in pancreatic cancer cells. Oncol Lett 2016;12:3499-505. [PMID: 27900027 DOI: 10.3892/ol.2016.5097] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
38 Azzarà A, Chiaramonte A, Filomeni E, Pinto B, Mazzoni S, Piaggi S, Angela Guzzardi M, Bruschi F, Iozzo P, Scarpato R. Increased level of DNA damage in some organs of obese Zucker rats by γ-H2AX analysis. Environ Mol Mutagen 2017;58:477-84. [PMID: 28714549 DOI: 10.1002/em.22115] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
39 Kassardjian A, Wang HL. SMAD4-Expressing Pancreatic Ductal Adenocarcinomas Have Better Response to Neoadjuvant Therapy and Significantly Lower Lymph Node Metastasis Rates. Pancreas 2020;49:1153-60. [PMID: 32897998 DOI: 10.1097/MPA.0000000000001636] [Reference Citation Analysis]
40 Freeman AJ, Ooi CY. Pancreatitis and pancreatic cystosis in Cystic Fibrosis. Journal of Cystic Fibrosis 2017;16:S79-86. [DOI: 10.1016/j.jcf.2017.07.004] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 4.4] [Reference Citation Analysis]
41 Archibugi L, Graglia B, Valente R, Stigliano S, Roberto M, Capalbo C, Marchetti P, Nigri G, Capurso G. Gynecological and reproductive factors and the risk of pancreatic cancer: A case-control study. Pancreatology. 2020;20:1149-1154. [PMID: 32800645 DOI: 10.1016/j.pan.2020.07.398] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
42 Magouliotis DE, Sakellaridis N, Dimas K, Tasiopoulou VS, Svokos KA, Svokos AA, Zacharoulis D. In Silico Transcriptomic Analysis of the Chloride Intracellular Channels (CLIC) Interactome Identifies a Molecular Panel of Seven Prognostic Markers in Patients with Pancreatic Ductal Adenocarcinoma. Curr Genomics 2020;21:119-27. [PMID: 32655306 DOI: 10.2174/1389202921666200316115631] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
43 Liberati D, Marzinotto I, Brigatti C, Dugnani E, Pasquale V, Reni M, Balzano G, Falconi M, Piemonti L, Lampasona V. No evidence of pancreatic ductal adenocarcinoma specific autoantibodies to Ezrin in a liquid phase LIPS immunoassay. Cancer Biomark 2018;22:351-7. [PMID: 29660901 DOI: 10.3233/CBM-181218] [Reference Citation Analysis]
44 Butt SA, Lidegaardi Ø, Skovlund C, Hannaford PC, Iversen L, Fielding S, Mørch LS. Hormonal contraceptive use and risk of pancreatic cancer-A cohort study among premenopausal women. PLoS One 2018;13:e0206358. [PMID: 30376560 DOI: 10.1371/journal.pone.0206358] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
45 Peisl S, Mellenthin C, Vignot L, Gonelle-Gispert C, Bühler L, Egger B. Therapeutic targeting of STAT3 pathways in pancreatic adenocarcinoma: A systematic review of clinical and preclinical literature. PLoS One 2021;16:e0252397. [PMID: 34138876 DOI: 10.1371/journal.pone.0252397] [Reference Citation Analysis]
46 Schulte A, Pandeya N, Fawcett J, Fritschi L, Klein K, Risch HA, Webb PM, Whiteman DC, Neale RE. Association between family cancer history and risk of pancreatic cancer. Cancer Epidemiol. 2016;45:145-150. [PMID: 27810486 DOI: 10.1016/j.canep.2016.10.005] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
47 Youngwirth LM, Nussbaum DP, Thomas S, Adam MA, Blazer DG 3rd, Roman SA, Sosa JA. Nationwide trends and outcomes associated with neoadjuvant therapy in pancreatic cancer: An analysis of 18 243 patients. J Surg Oncol 2017;116:127-32. [PMID: 28407261 DOI: 10.1002/jso.24630] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 8.4] [Reference Citation Analysis]
48 Stillström D, Nilsson H, Jesse M, Peterhans M, Jonas E, Freedman J. A new technique for minimally invasive irreversible electroporation of tumors in the head and body of the pancreas. Surg Endosc 2017;31:1982-5. [PMID: 27572065 DOI: 10.1007/s00464-016-5173-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
49 Kassardjian A, Stanzione N, Wang HL. Comparative Accuracy of Tumor Size Assessment and Stage Analysis by Imaging Modalities Versus Gross Examination for Pancreatic Ductal Adenocarcinoma. Pancreas 2019;48:223-7. [PMID: 30629023 DOI: 10.1097/MPA.0000000000001233] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
50 Penheiter AR, Deelchand DK, Kittelson E, Damgard SE, Murphy SJ, O'Brien DR, Bamlet WR, Passow MR, Smyrk TC, Couch FJ, Vasmatzis G, Port JD, Marjańska M, Carlson SK. Identification of a pyruvate-to-lactate signature in pancreatic intraductal papillary mucinous neoplasms. Pancreatology 2018;18:46-53. [PMID: 29170050 DOI: 10.1016/j.pan.2017.11.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
51 Ghidini M, Lampis A, Mirchev MB, Okuducu AF, Ratti M, Valeri N, Hahne JC. Immune-Based Therapies and the Role of Microsatellite Instability in Pancreatic Cancer. Genes (Basel) 2020;12:33. [PMID: 33383713 DOI: 10.3390/genes12010033] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
52 Cazacu IM, Luzuriaga Chavez AA, Saftoiu A, Bhutani MS. Psychological impact of pancreatic cancer screening by EUS or magnetic resonance imaging in high-risk individuals: A systematic review. Endosc Ultrasound. 2019;8:17-24. [PMID: 30246710 DOI: 10.4103/eus.eus_25_18] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
53 Honda K, Srivastava S. Potential usefulness of apolipoprotein A2 isoforms for screening and risk stratification of pancreatic cancer. Biomark Med 2016;10:1197-207. [PMID: 27673558 DOI: 10.2217/bmm-2016-0209] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
54 Majumder S, Chari ST, Ahlquist DA. Molecular detection of pancreatic neoplasia: Current status and future promise. World J Gastroenterol 2015; 21(40): 11387-11395 [PMID: 26526068 DOI: 10.3748/wjg.v21.i40.11387] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
55 Bujanda L, Herreros-Villanueva M. Pancreatic Cancer in Lynch Syndrome Patients. J Cancer 2017;8:3667-74. [PMID: 29151953 DOI: 10.7150/jca.20750] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.6] [Reference Citation Analysis]
56 Cai J, Chen H, Lu M, Zhang Y, Lu B, You L, Zhang T, Dai M, Zhao Y. Advances in the epidemiology of pancreatic cancer: Trends, risk factors, screening, and prognosis. Cancer Lett 2021;520:1-11. [PMID: 34216688 DOI: 10.1016/j.canlet.2021.06.027] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
57 Tan M, Schaffalitzky de Muckadell OB, Laursen SB. Unchanged mortality in patients with acute cholangitis despite an increase in malignant etiologies – a 25-year epidemiological study. Scandinavian Journal of Gastroenterology 2019;54:335-41. [DOI: 10.1080/00365521.2019.1585568] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
58 Ben Q, Zhong J, Fei J, Chen H, Yv L, Tan J, Yuan Y. Risk Factors for Sporadic Pancreatic Neuroendocrine Tumors: A Case-Control Study. Sci Rep 2016;6:36073. [PMID: 27782199 DOI: 10.1038/srep36073] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
59 Vieira NF, Serafini LN, Novais PC, Neto FSL, Cirino MLA, Kemp R, Ardengh JC, Saggioro FP, Gaspar AF, Sankarankutty AK, Júnior JRL, Tirapelli DPDC, Dos Santos JS. The role of circulating miRNAs and CA19-9 in pancreatic cancer diagnosis. Oncotarget 2021;12:1638-50. [PMID: 34434493 DOI: 10.18632/oncotarget.28038] [Reference Citation Analysis]
60 Liang DH, Shirkey BA, Rosenberg WR, Martinez S. Clinical outcomes of pancreaticoduodenectomy in octogenarians: a surgeon's experience from 2007 to 2015. J Gastrointest Oncol 2016;7:540-6. [PMID: 27563443 DOI: 10.21037/jgo.2016.03.04] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
61 Hodolic M, Ambrosini V, Fanti S. Potential use of radiolabelled neurotensin in PET imaging and therapy of patients with pancreatic cancer. Nucl Med Commun 2020;41:411-5. [PMID: 32168264 DOI: 10.1097/MNM.0000000000001172] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
62 Witvliet-van Nierop J, de van der Schueren M, Scheffer H, Vroomen L, Meijerink M, van Bodegraven A, Wierdsma N. Exocrine pancreatic and enterocyte function in patients with advanced pancreatic cancer. Clinical Nutrition 2019;38:2778-82. [DOI: 10.1016/j.clnu.2018.12.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
63 Pavlidis ET, Lambropoulou M, Symeonidis NG, Anagnostopoulos C, Tsaroucha A, Kotini A, Nikolaidou C, Kiziridou A, Simopoulos C. The Immunohistochemical Expression MTA 1 Protein and its Prognostic Value in Pancreatic Cancer. J Invest Surg 2018;31:142-50. [PMID: 28635511 DOI: 10.1080/08941939.2017.1280565] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
64 Wei D, Zaid MM, Katz MH, Prakash LR, Kim M, Tzeng CD, Lee JE, Agrawal A, Rashid A, Wang H, Varadhachary G, Wolff RA, Tamm EP, Bhosale PR, Maitra A, Koay EJ. Clinicopathological correlation of radiologic measurement of post-therapy tumor size and tumor volume for pancreatic ductal adenocarcinoma. Pancreatology. 2021;21:200-207. [PMID: 33221151 DOI: 10.1016/j.pan.2020.11.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
65 Magouliotis DE, Tasiopoulou VS, Dimas K, Sakellaridis N, Svokos KA, Svokos AA, Zacharoulis D. Transcriptomic analysis of the Aquaporin (AQP) gene family interactome identifies a molecular panel of four prognostic markers in patients with pancreatic ductal adenocarcinoma. Pancreatology 2019;19:436-42. [PMID: 30826259 DOI: 10.1016/j.pan.2019.02.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
66 Sánchez Morales G, Moguel Valladares R, Flores Maza J, Clemente Gutiérrez U, Sánchez-garcía Ramos E, Domínguez Rosado I, Chan Núñez L. Pancreatic ductal adenocarcinoma: Eleven years of experience at a tertiary care hospital center. Revista de Gastroenterología de México (English Edition) 2021;86:118-24. [DOI: 10.1016/j.rgmxen.2020.04.005] [Reference Citation Analysis]
67 Gallego J, López C, Pazo-cid R, López-ríos F, Carrato A. Biomarkers in pancreatic ductal adenocarcinoma. Clin Transl Oncol 2017;19:1430-7. [DOI: 10.1007/s12094-017-1691-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
68 Whitcomb DC;  North American Pancreatitis Study Group. Pancreatitis: TIGAR-O Version 2 Risk/Etiology Checklist With Topic Reviews, Updates, and Use Primers. Clin Transl Gastroenterol. 2019;10:e00027. [PMID: 31166201 DOI: 10.14309/ctg.0000000000000027] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 15.5] [Reference Citation Analysis]
69 Direito I, Paulino J, Vigia E, Brito MA, Soveral G. Differential expression of aquaporin-3 and aquaporin-5 in pancreatic ductal adenocarcinoma. J Surg Oncol 2017;115:980-96. [PMID: 28471475 DOI: 10.1002/jso.24605] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 5.2] [Reference Citation Analysis]
70 Cannistrà M, Ruggiero M, Zullo A, Serafini S, Grande R, Nardo B. Metastases of pancreatic adenocarcinoma: A systematic review of literature and a new functional concept. Int J Surg 2015;21 Suppl 1:S15-21. [PMID: 26123383 DOI: 10.1016/j.ijsu.2015.04.093] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
71 Martinez-Useros J, Garcia-Foncillas J. The Role of BRCA2 Mutation Status as Diagnostic, Predictive, and Prognosis Biomarker for Pancreatic Cancer. Biomed Res Int 2016;2016:1869304. [PMID: 28078281 DOI: 10.1155/2016/1869304] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
72 Kiss B, Mikó E, Sebő É, Toth J, Ujlaki G, Szabó J, Uray K, Bai P, Árkosy P. Oncobiosis and Microbial Metabolite Signaling in Pancreatic Adenocarcinoma. Cancers (Basel) 2020;12:E1068. [PMID: 32344895 DOI: 10.3390/cancers12051068] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
73 Kassardjian A, Stanzione N, Donahue TR, Wainberg ZA, Damato L, Wang HL. Impact of Changes in the American Joint Committee on Cancer Staging Manual, Eighth Edition, for Pancreatic Ductal Adenocarcinoma. Pancreas 2019;48:876-82. [PMID: 31268985 DOI: 10.1097/MPA.0000000000001349] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
74 Monroy-Iglesias MJ, Dolly S, Sarker D, Thillai K, Van Hemelrijck M, Santaolalla A. Pancreatic Cancer Exposome Profile to Aid Early Detection and Inform Prevention Strategies. J Clin Med 2021;10:1665. [PMID: 33924591 DOI: 10.3390/jcm10081665] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
75 Qian CJ, Qi YX, Zhong S, Zeng JP, Chen XY, Yao J. Mitogen-activated protein kinase inhibition enhances the antitumor effects of sporamin in human pancreatic cancer cells. Oncol Lett 2018;16:1237-42. [PMID: 30061945 DOI: 10.3892/ol.2018.8746] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
76 Permuth JB, Chen DT, Yoder SJ, Li J, Smith AT, Choi JW, Kim J, Balagurunathan Y, Jiang K, Coppola D, Centeno BA, Klapman J, Hodul P, Karreth FA, Trevino JG, Merchant N, Magliocco A, Malafa MP, Gillies R. Linc-ing Circulating Long Non-coding RNAs to the Diagnosis and Malignant Prediction of Intraductal Papillary Mucinous Neoplasms of the Pancreas. Sci Rep 2017;7:10484. [PMID: 28874676 DOI: 10.1038/s41598-017-09754-5] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 6.2] [Reference Citation Analysis]
77 Desai V, Patel K, Sheth R, Barlass U, Chan YM, Sclamberg J, Bishehsari F. Pancreatic Fat Infiltration Is Associated with a Higher Risk of Pancreatic Ductal Adenocarcinoma. Visc Med 2020;36:220-6. [PMID: 32775353 DOI: 10.1159/000507457] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
78 Ma YY, Shi JJ, Chen JB, Xu KC, Niu LZ. Irreversible electroporation for liver metastasis from pancreatic cancer: A case report. World J Clin Cases 2020; 8(2): 390-397 [PMID: 32047790 DOI: 10.12998/wjcc.v8.i2.390] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
79 Syed AR, Carleton NM, Horne Z, Dhawan A, Bedi G, Kochhar G, Morrissey S, Williams H, Atkinson D, Schiffman S, Monga D, Lupetin A, Kirichenko A, Mitre M, Dhawan M, Kulkarni A, Thakkar S. Survival Trends for Resectable Pancreatic Cancer Using a Multidisciplinary Conference: the Impact of Post-operative Chemotherapy. J Gastrointest Cancer 2020;51:836-43. [PMID: 31605289 DOI: 10.1007/s12029-019-00303-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
80 Allenson K, Castillo J, San Lucas FA, Scelo G, Kim DU, Bernard V, Davis G, Kumar T, Katz M, Overman MJ, Foretova L, Fabianova E, Holcatova I, Janout V, Meric-Bernstam F, Gascoyne P, Wistuba I, Varadhachary G, Brennan P, Hanash S, Li D, Maitra A, Alvarez H. High prevalence of mutant KRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients. Ann Oncol 2017;28:741-7. [PMID: 28104621 DOI: 10.1093/annonc/mdx004] [Cited by in Crossref: 188] [Cited by in F6Publishing: 192] [Article Influence: 37.6] [Reference Citation Analysis]
81 Rahman SH, Urquhart R, Molinari M. Neoadjuvant therapy for resectable pancreatic cancer. World J Gastrointest Oncol 2017; 9(12): 457-465 [PMID: 29290916 DOI: 10.4251/wjgo.v9.i12.457] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
82 Lewis AR, Valle JW, McNamara MG. Pancreatic cancer: Are "liquid biopsies" ready for prime-time? World J Gastroenterol 2016; 22(32): 7175-7185 [PMID: 27621566 DOI: 10.3748/wjg.v22.i32.7175] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
83 Dugnani E, Sordi V, Pellegrini S, Chimienti R, Marzinotto I, Pasquale V, Liberati D, Balzano G, Doglioni C, Reni M, Gandolfi A, Falconi M, Lampasona V, Piemonti L. Gene expression analysis of embryonic pancreas development master regulators and terminal cell fate markers in resected pancreatic cancer: A correlation with clinical outcome. Pancreatology 2018;18:945-53. [PMID: 30293872 DOI: 10.1016/j.pan.2018.09.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
84 Pavlidis ET, Pavlidis TE. Current Molecular and Genetic Aspects of Pancreatic Cancer, the Role of Metastasis Associated Proteins (MTA): A Review. J Invest Surg 2018;31:54-66. [PMID: 28060554 DOI: 10.1080/08941939.2016.1269854] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
85 Arteta AA, Milanes-Yearsley M, Cardona-Castro N. Cholangiocyte derived carcinomas and local microbiota. J Hepatobiliary Pancreat Sci 2020. [PMID: 32902144 DOI: 10.1002/jhbp.826] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
86 Tseng CH. Sitagliptin and pancreatic cancer risk in patients with type 2 diabetes. Eur J Clin Invest 2016;46:70-9. [PMID: 26584246 DOI: 10.1111/eci.12570] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 3.3] [Reference Citation Analysis]
87 Whitcomb DC, Shelton CA, Brand RE. Genetics and Genetic Testing in Pancreatic Cancer. Gastroenterology. 2015;149:1252-1264.e4. [PMID: 26255042 DOI: 10.1053/j.gastro.2015.07.057] [Cited by in Crossref: 43] [Cited by in F6Publishing: 44] [Article Influence: 6.1] [Reference Citation Analysis]